YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models - PubMed (original) (raw)

doi: 10.1124/jpet.105.085126. Epub 2005 Mar 22.

Affiliations

• PMID: 15784655
• DOI: 10.1124/jpet.105.085126

Free article

YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models

Shiow-Lin Pan et al. J Pharmacol Exp Ther. 2005 Jul.

Free article

Abstract

Angiogenesis is a process that involves endothelial cell proliferation, migration, invasion, and tube formation, and inhibition of these processes has implications for angiogenesis-mediated disorders. The purpose of this study was to evaluate the antiangiogenic efficacy of YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] in well characterized in vitro and in vivo systems. YC-1 inhibited the ability of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in a dose-dependent manner to induce proliferation, migration, and tube formation in human umbilical vascular endothelial cells; these outcomes were evaluated using [3H]thymidine incorporation, transwell chamber, and Matrigel-coated slide assays, respectively. YC-1 inhibited VEGF- and bFGF-induced p42/p44 mitogen-activated protein kinase and Akt phosphorylation as well as protein kinase C alpha translocation using Western blot analysis. The effect of YC-1 on angiogenesis in vivo was evaluated using the mouse Matrigel implant model. YC-1 administered orally in doses of 1 to 100 mg/kg/day inhibited VEGF- and bFGF-induced neovascularization in a dose-dependent manner over 7 days. These results indicate that YC-1 has antiangiogenic activity at very low doses. Moreover, in transplantable murine tumor models, YC-1 administered orally displayed a high degree of antitumor activity (treatment-to-control life span ratio > 175%) without cytotoxicity. YC-1 may be useful for treating angiogenesis-dependent human diseases such as cancer.

PubMed Disclaimer

Similar articles

• The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo.
  Peng CY, Pan SL, Pai HC, Tsai AC, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM. Peng CY, et al. Shock. 2010 Dec;34(6):580-5. doi: 10.1097/SHK.0b013e3181df00a3. Shock. 2010. PMID: 20351626
• Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
  Li Y, Zhao X, Tang H, Zhong Z, Zhang L, Xu R, Li S, Wang Y. Li Y, et al. Urol Int. 2012;88(1):95-101. doi: 10.1159/000331881. Epub 2011 Oct 25. Urol Int. 2012. PMID: 22041818
• YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.
  Chiang WC, Teng CM, Lin SL, Chen YM, Tsai TJ, Hsieh BS. Chiang WC, et al. Eur J Pharmacol. 2005 Jul 4;517(1-2):1-10. doi: 10.1016/j.ejphar.2005.04.046. Eur J Pharmacol. 2005. PMID: 15950964
• LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo.
  Gao JJ, Xue X, Gao ZH, Cui SX, Cheng YN, Xu WF, Tang W, Qu XJ. Gao JJ, et al. Microvasc Res. 2011 Sep;82(2):122-30. doi: 10.1016/j.mvr.2011.05.008. Epub 2011 Jun 12. Microvasc Res. 2011. PMID: 21664364 Review.
• Salutary properties of YC-1 in the cardiovascular and hematological systems.
  Tulis DA. Tulis DA. Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):343-59. doi: 10.2174/1568016043356200. Curr Med Chem Cardiovasc Hematol Agents. 2004. PMID: 15320784 Review.

Cited by

• The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
  Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. Carroll CE, et al. Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24. Int J Oncol. 2013. PMID: 23123638 Free PMC article.
• YC-1 Prevents Tumor-Associated Tissue Factor Expression and Procoagulant Activity in Hypoxic Conditions by Inhibiting p38/NF-κB Signaling Pathway.
  Hsieh KY, Wei CK, Wu CC. Hsieh KY, et al. Int J Mol Sci. 2019 Jan 9;20(2):244. doi: 10.3390/ijms20020244. Int J Mol Sci. 2019. PMID: 30634531 Free PMC article.
• Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.
  Lin YC, Chen YF, Tseng LS, Lee YH, Morris-Natschke SL, Kuo SC, Yang NS, Lee KH, Huang LJ. Lin YC, et al. Eur J Med Chem. 2016 Mar 3;110:98-114. doi: 10.1016/j.ejmech.2016.01.004. Epub 2016 Jan 7. Eur J Med Chem. 2016. PMID: 26820553 Free PMC article.
• YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells.
  Lee MR, Lin C, Lu CC, Kuo SC, Tsao JW, Juan YN, Chiu HY, Lee FY, Yang JS, Tsai FJ. Lee MR, et al. Biomedicine (Taipei). 2017 Jun;7(2):12. doi: 10.1051/bmdcn/2017070205. Epub 2017 Jun 14. Biomedicine (Taipei). 2017. PMID: 28612710 Free PMC article.
• Methylene blue inhibits angiogenesis in chick chorioallontoic membrane through a nitric oxide-independent mechanism.
  Zacharakis N, Tone P, Flordellis CS, Maragoudakis ME, Tsopanoglou NE. Zacharakis N, et al. J Cell Mol Med. 2006 Apr-Jun;10(2):493-8. doi: 10.1111/j.1582-4934.2006.tb00414.x. J Cell Mol Med. 2006. PMID: 16796814 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • CORE
  • Elsevier Science
  • HighWire

• Other Literature Sources

  • The Lens - Patent Citations Database